Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 1,226–1,250 of 27,380 studies, newest first · page 50 of 1096.

May 2026 25

  1. 2026-05-14

    Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation

    ✓ Peer-reviewed Drug development Journal of the American Chemical Society

    Key finding: Liraglutide was highly effective at suppressing primary nucleation with a very low KIP value, and it demonstrated an additional modest inhibition of secondary nucleation. +2 more findings

  2. 2026-05-14

    County-Level Ecological Association Between Glyphosate Exposure and Chronic Disease Mortality in Midwestern US Agricultural Communities

    ✓ Peer-reviewed Risk factors Cureus

    Key finding: Concerns have been raised regarding potential long-term health effects associated with environmental exposure. +2 more findings

  3. 2026-05-14

    Overcoming the blood–brain barrier in Alzheimer's disease: translational perspectives on advanced drug delivery platforms

    ✓ Peer-reviewed Disease mechanisms Frontiers in Neuroscience

    Key finding: These properties can improve drug solubility, stability, pharmacokinetics, and targeted brain accumulation while reducing systemic toxicity. +4 more findings

  4. 2026-05-14

    TDP-43: [GU]-ardian of the transcriptome

    ✓ Peer-reviewed Brain tissue and pathology Molecular Neurodegeneration

    Key finding: TDP-43 nuclear depletion and cytoplasmic aggregation are well-established pathological features in affected neurons and glia of neurodegenerative diseases, and accumulating evidence suggests that loss of TDP-43-mediated splicing repression occurs presymptomatically in disease.

  5. 2026-05-14

    The bidirectional association of epilepsy with Alzheimer's disease and other neurodegenerative dementias: A longitudinal observational study on the UK Biobank

    ✓ Peer-reviewed Long-term cohort studies Journal of Alzheimer s Disease

    Key finding: Our findings reinforce the notion of a bidirectional association between epilepsy and AD, providing proof-of-concept that epilepsy, especially late-onset, may be successfully integrated into AD risk frameworks. +4 more findings

  6. 2026-05-14

    predALZ: An Ensemble Learning Framework for Identifying Genetic Biomarkers in Familial Alzheimer’s Disease

    ✓ Peer-reviewed Genetics Current Drug Targets

    Key finding: The predALZ framework achieved 94% accuracy on an independent test set and approximately 96% accuracy in cross-validation for Alzheimer-related driver gene prediction. +4 more findings

  7. 2026-05-14

    Glial Fibrillary Acidic Protein and Neurofilament Light Reference Intervals in Healthy Individuals

    ✓ Peer-reviewed Biomarkers JAMA Network Open

    Key finding: In 7989 cognitively unimpaired participants (median [range] age, 54 [30-90] years; 4877 [61.3%] female; mean [SD] BMI, 25.9 [4.2]; mean [SD] eGFR, 80.7 [14.7] mL/min/1.73 m2), older age, lower BMI, and reduced kidney function were associated with increased NfL and GFAP concentrations; female sex was associated with increased GFAP concentrations. +4 more findings

  8. 2026-05-13

    Biopsychosocial risk factors for Alzheimer’s disease and related dementias in UK immigrants from the Middle East and North Africa (MENA)

    ⚠ Preprint — not yet peer-reviewed Risk factors medRxiv

    Key finding: MENA immigrants exhibited a distinct and adverse risk profile characterized by greater socioeconomic deprivation, higher exposure to air pollution, poorer diet quality, lower physical activity, worse sleep, and higher smoking prevalence compared to European immigrant groups. +3 more findings

    Scored 34 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

  9. 2026-05-13

    MIND diet moderates the associations between cerebrovascular and neurodegenerative disease burden and cognition

    ✓ Peer-reviewed Prevention trials Frontiers in Nutrition

    Key finding: The MIND diet may buffer the cognitive consequences of cerebrovascular pathology and cortical atrophy in older adults at elevated dementia risk and promote cognitive resilience over general healthy eating guidelines. +1 more finding

  10. 2026-05-13

    Extracellular Vesicles in Alzheimer’s Disease: Mechanisms, Immunotherapy Links, and Clinical Translation

    ✓ Peer-reviewed Disease mechanisms Current Pharmaceutical Design

    Key finding: Nevertheless, emerging data show that lipid metabolism is an important and well-established aspect of AD pathophysiology rather than a new theory. +4 more findings

  11. 2026-05-13

    Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial

    ✓ Peer-reviewed Clinical trials Neurology: Clinical Practice

    Key finding: Donanemab, a monoclonal antibody targeting the insoluble form of β-amyloid found in plaques, significantly slows cognitive and functional decline of AD in participants with mild cognitive impairment (MCI) or mild AD-related dementia. +3 more findings

  12. 2026-05-12

    ALZHEIMER PRECOCE: FATORES PREDISPONENTES, DIAGNÓSTICO E MANEJO

    ✓ Peer-reviewed Risk genes beyond APOE Revista Ibero-Americana de Humanidades, Ciências e Educação

    Key finding: Esse artigo buscou abordar a Doença de Alzheimer de Início Precoce (DAIP) acerca do curso clínico, dos fatores predisponentes e do manejo, por meio de uma revisão de literatura, com ênfase na diferenciação entre DAIP e Doença de Alzheimer de Início Tardio (DAIT), incluindo artigos publicados entre 2015 e 2025, obtidos nas bases de dados “Alzheimer's Association”, “ScienceDirect”, “Cochrane” e “PubMed”, utilizando as palavras-chave “Alzheimer”, “early” e “on-set”, com o conectivo AND. +3 more findings

  13. 2026-05-12

    Plasma Phosphorylated Tau217–A Pivotal Plasma Biomarker for Predicting the Progression of Mild Cognitive Impairment to Alzheimer’s Disease: A Reanalysis of ADNI Data

    ✓ Peer-reviewed Mild cognitive impairment Journal of Clinical and Experimental Neuropsychology

    Key finding: P-tau217 demonstrated the most significant inter-group differences, the highest hazard ratio, and best distinguished MCI-Converters from MCI-Nonconverters, with its discriminative performance comparable to that of Aβ-PET measures and multi-plasma biomarker models. +4 more findings

  14. 2026-05-12

    Biomarkører for Alzheimers sykdom – et fremskritt for hvem?

    ✓ Peer-reviewed Biomarkers Tidsskrift for Den norske legeforening

    Key finding: 12.05.2026: Debatt - En enkel blodprøve kan nå påvise fosforylert tau-protein 217 (p-tau217) – et biologisk tegn på Alzheimers sykdom, som kan være til stede mange år før de første symptomene viser seg.

  15. 2026-05-12
  16. 2026-05-12

    Hearing aid effectiveness and probable dementia risk across 33 countries: A pooled analysis of seven cohorts

    ✓ Peer-reviewed Prevention and risk Cell Reports Medicine

    Key finding: Given the inconsistent evidence regarding hearing aid use and reduced dementia risk, this study evaluates whether hearing aid use, particularly effective use, is associated with lower probable dementia risk among hearing-impaired older adults. +1 more finding

  17. 2026-05-11

    Alzheimer's Disease Co-Pathology and Cognitive Impairment in Amyotrophic Lateral Sclerosis

    ✓ Peer-reviewed Brain tissue and pathology Annals of neurology

    Key finding: Compared with healthy controls, patients with ALS - particularly those with cognitive impairment (ALSci) or ALS-FTD - showed elevated AD-related biomarkers. +4 more findings

  18. 2026-05-11

    Fluid Biomarkers of Cognitive Impairments Following Traumatic Brain Injury: A Systematic Review and Meta Analysis

    ✓ Peer-reviewed Disease mechanisms International journal of molecular sciences

    Key finding: Among these, neurofilament light chain (NfL), ubiquitin C-terminal hydrolase L1, total tau, and glial fibrillary acidic protein (GFAP) were consistently associated with CI and brain atrophy across various TBI severities and stages. +2 more findings

  19. 2026-05-11

    A longitudinal analysis of T1-weighted MRI features associated with progression from mild cognitive impairment to Alzheimer’s disease

    ✓ Peer-reviewed Mild cognitive impairment BMC Medical Imaging

    Key finding: We identified 8 brain structural features from 192 MRI features that were associated with the risk of MCI progressing to AD, including: left hippocampus, left inferior lateral ventricle, left amygdala, right middle temporal gyrus, left fusiform gyrus, right amygdala, left cortical total volume, and brain parenchyma total volume. +3 more findings

  20. 2026-05-11

    A deep hybrid CNN-BiLSTM-BiGRU architecture with explainability for mild cognitive impairment detection using EEG

    ✓ Peer-reviewed Mild cognitive impairment Brain Informatics

    Key finding: These results demonstrate robust, interpretable EEG-based MCI detection with potential clinical utility.

  21. 2026-05-11

    Incidence and Prevalence of Dementia With Lewy Bodies

    ✓ Peer-reviewed How common it is JAMA Neurology

    Key finding: From 2520 records screened, 16 population-based studies were included and 12 contributed to meta-analyses. +4 more findings

  22. 2026-05-11

    Perspectives in dementia risk reduction – food for thought

    ✓ Peer-reviewed Prevention and risk Neurodegenerative Disease Management

    Key finding: Although the benefits of single-agent nutrient supplementation are unclear, the LipiDiDiet trial has indicated that multinutrient supplementation with Fortasyn Connect may have the potential to improve cognitive function and decrease disease progression in individuals with prodromal Alzheimer's disease. +1 more finding

  23. 2026-05-11

    Non-economic social deprivation and cognitive functioning later in life: Results from the DELCODE study

    ✓ Peer-reviewed Risk factors Journal of Alzheimer s Disease

    Key finding: Our findings suggest that non-economic social deprivation, especially in terms of access to a grocery store, pharmacy, postal office, and bus stop, might be relevant for maintaining cognitive functioning in old age. +3 more findings

  24. 2026-05-10

    The social value of lecanemab for patients with early Alzheimer's disease in Japan

    ✓ Peer-reviewed Costs and economics Journal of Alzheimer's Disease

    Key finding: In AD, where the progression of the illness spans a long period and had a significant impact on families and society, narrowly defined value assessments were not sufficient, indicating the need to consider broader social value.

  25. 2026-05-09

    Physical activity, falls, and dementia risk in adults aged ≥ 60: evidence from three cohorts

    ✓ Peer-reviewed Clinical safety International Journal of Behavioral Nutrition and Physical Activity

    Key finding: Over a median follow-up of 5.9-7.9 years, 3,492 dementia cases were identified. +4 more findings

Browse the library by subject, with the full score breakdown →